Warfarin is a traditional Oral AntiCoagulant (OAC) for stroke prevention in patients with Non Valvular Atrial Fibrillation (NVAF). The Non Vitamin K OACs (NOACs), firstly dabigatran (directly targeting the enzymatic activity of thrombin) and then rivaroxaban, apixaban and edoxaban (targeting the enzymatic activity of factor Xa), have been approved for use in patients with NVAF. Although several studies have reported the possible association between warfarin and an increased risk of osteoporotic fracture [1–4], only one population-based cohort study was conducted to compare the risk of dabigatran and warfarin, showing a lower risk for dabigatran compared with warfarin [5].
